Bemarituzumab with FOLFOX6 in FGFR2b+ advanced gastric/gastroesophageal junction adenocarcinoma

Clinical trials participation is directly influenced by the information received by cancer patients and caregivers

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Incidence and trends of HPV-related cancers in the United States

ASCO 2021: Latest on PARPi and other treatments for mCRPC

Long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC

ASCO 2021: Renal cancer roundup

Olaparib improves disease-free survival in high-risk early-stage HER2-negative breast cancer with BRCA 1/2 mutations

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

European Cancer Organisation - Time to Act